One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Praxis Precision Medicines, Inc. (PRAX): score, valuation & FAQ
Praxis Precision Medicines, Inc. (PRAX) is a Biotechnology company that scores 36.7 out of 100 on the Bull Rankings quality-growth model — a weak reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (A) and D/E (A), while FCF (F) rate weaker.
Is PRAX a good stock to buy?
Bull Rankings scores PRAX 36.7 out of 100 on its quality-growth model, which is a weak reading. That is driven by Rev (A) and D/E (A). A score is a quantitative screen of Praxis Precision Medicines, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does PRAX score 36.7 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). PRAX earns its highest marks on Rev (A) and D/E (A), and is held back by FCF (F). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is PRAX overvalued or undervalued?
We don't compute a reliable discounted-cash-flow value for PRAX — typically because it is not yet consistently profitable or free-cash-flow positive — so its valuation rests on growth and price-to-sales rather than on earnings-based intrinsic value. Judge it on the trajectory of the business, not a single multiple.
What are the main risks of investing in PRAX?
Free cash flow is negative (-$282m) — capital raises or debt issuance likely required; dilution / leverage risk. Beta 2.76 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. ROE -23% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.